MACROGENICS, INC. Income (Loss) from Continuing Operations, Per Diluted Share
MACROGENICS, INC. (MGNX) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$1.10 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-08-14
- MACROGENICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2026-06-30 was -$1.10.
- MACROGENICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2025-06-30 was -$0.67.
- MACROGENICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2021 was -$3.37.
- MACROGENICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2020 was -$2.47.
- MACROGENICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2019 was -$3.16.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|
| 2026-06-30 | -$1.10 10-Q · filed 2026-08-14 | -$1.75 10-Q · filed 2026-08-14 | |
| 2025-06-30 | -$0.67 10-Q · filed 2026-08-14 | -$1.34 10-Q · filed 2026-08-14 | |
| 2021-12-31 | -$3.37 10-K · filed 2022-02-24 | ||
| 2020-12-31 | -$2.47 10-K · filed 2022-02-24 | ||
| 2019-12-31 | -$3.16 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |